logo-loader
MiningGeneral mining & base metals
Tertiary Minerals PLC

Tertiary will assess decision to deny exploitation concession at Storuman

Tertiary's lawyer has recommended an appeal against the decision

1547537807_shutterstock_605354843.jpg
Fluorspar has been declared a strategic mineral by the EU and China

Tertiary Minerals plc (LON:TYM) will assess a decision by the Swedish Mining Inspectorate to reject its application for an exploitation concession.

The Mining Inspectorate stated that the economic aspects point in favour of granting the concession, and the socio-economic benefits to the community would be considerable.

READ: Tertiary Minerals offers direct exposure to fluorspar, a material deemed strategic and critical by the EU, US and China alike

However, the Mining Inspectorate also found that co-existence with reindeer husbandry would e compromised.

The company's Swedish lawyer has commented that the Mining Inspectorate has not fully assessed the case regarding the protective and mitigation measures suggested by Tertiary and has instead only taken the local authority’s assessment into account.

The lawyer has recommended that Tertiary appeal the decision to the Government

Tertiary will now fully assess the decision and intends to lodge an appeal with the Swedish government in line with the advice of its Swedish lawyer

"We are disappointed that the Mining Inspectorate has taken this decision based on the application in its current form,” said managing director Richard Clemmy.

“We, together with our Swedish Lawyers, will appeal the decision to the Swedish Government and will now assess the future options available to the Company".

Quick facts: Tertiary Minerals PLC

Price: £0.00

Market: AIM
Market Cap: £1.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

N4 Pharma's Nuvec platform 'on a clear path' towards clinical trials

N4 Pharma PLC (LON:N4P) CEO Nigel Theobald speaks to Proactive London's Andrew Scott following the release of the firm's interim results to June 2019. He says it's been an incredibly active period for them where, among a number of developments, they've confirmed that Nuvec® works for both DNA...

11 minutes ago

2 min read